Reduction in the Company's Expenses Through New Partnerships, Joint Research and Public Subsidies
First written in FY2017. 8 of 15 entries say "Restated". Latest entry: FY2026-H1.
25 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「In addition, we have entered into a joint research agreement with NIBN concerning “Drug Discovery through Activation of Tumour Suppressors: Isolation of New Suppressor Genes (Products) and Drug Discovery Development through Analysis of Their Functions.”」
Regarding research and development alliances, an additional joint research agreement with NIBN concerning drug discovery through activation of tumour suppressors has been disclosed. Together with the existing AI-based drug discovery platform research, research and development with AMED and Tokushima University, and licensing-out activities, research promotion through external alliances is expanding. - FY2025-H1AdvancedAnnual report
「In addition, because NIBIOHN has proprietary technology and expertise in applying artificial intelligence (AI) to drug discovery, we have entered into a joint research agreement, as of the date of submission of this document, concerning the “Development and Application of an AI-Based Drug Discovery Platform.” The purpose is to analyse information on proprietary compounds in our library using AI and identify compounds that could lead to new drug discovery.」
Regarding research and development alliances, a new joint research agreement with NIBIOHN concerning the development and application of an AI-based drug discovery platform has been disclosed. The joint research uses analysis of compound library information and the discovery of novel compounds as its means. - FY2023-Q3RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2023-Q1RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2022-Q3RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2022-Q1RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2021-Q3RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2021-Q2RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2021-Q1RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2020-Q3RestatedAnnual report
「As a group, we currently adopt a policy of maximising the possibility of commercialisation while keeping risk at a level that is reasonable from a management perspective, through active alliance agreements and research and development alliances with pharmaceutical companies and others.」
The policy of increasing the possibility of commercialisation while limiting the company's risk through alliance agreements and research and development alliances with pharmaceutical companies and others remains in place. - FY2019-Q3AdvancedAnnual report
「CPM entered into an outsourcing agreement with COSMO BIO COMPANY,LIMITED for peptide synthesis for cancer immunotherapy.」
As a specific example of an alliance and outsourcing arrangement aimed at reducing the company's cost burden and promoting the business, CPM entered into an outsourcing agreement with COSMO BIO COMPANY,LIMITED for peptide synthesis. - FY2018AdvancedAnnual report
「We will reduce the company's cost burden and promote the business while stabilising management by entering into new alliance agreements with pharmaceutical companies that serve as sources of revenue, conducting joint research and joint development with venture companies and academia, and actively using subsidy and grant programmes provided by public institutions.」
Measures to reduce the company's cost burden have expanded into specific joint research and alliance arrangements through CPM with IMS, Thermo Fisher Scientific, the Japanese Foundation for Cancer Research and others. - FY2018-Q2AdvancedAnnual report
「As of the date of submission of this document, the company had transferred its Tumor Immunology Analysis Department to CPM through a company split (simplified split). The department was a business division of the company engaged in research and development of cancer immunotherapies, including oncoantigens, and, as an advanced initiative, provided analysis services for T-cell and B-cell receptors using next-generation sequencing.」
The policy of promoting the business through new alliances and joint ventures has progressed to implementation, with TE's equity investment and business alliance, CPM's conversion into a joint venture, and the transfer of the business. - FY2018-Q1AdvancedAnnual report
「CPM will become a joint venture between the Company and Theragen Etex Co., Ltd. (headquartered in South Korea; CEO: Tae Soon (Samuel) Hwang; hereinafter, “TE”), as TE, which provides global next-generation sequencing analysis services for genomics, transcriptomics, epigenomics and other fields, has decided to make an equity investment in and enter into a business alliance with CPM.」
The previously stated policy of reducing the company's cost burden and promoting the business through new alliances and joint ventures has progressed to implementation, with TE's equity investment and business alliance and the establishment of a joint venture. - FY2017First statedAnnual report
「We will reduce the company's cost burden and promote the business while stabilising management by entering into new alliance agreements with pharmaceutical companies that serve as sources of revenue, conducting joint research and joint development with venture companies and academia, and actively using subsidy and grant programmes provided by public institutions.」
Specific measures to reduce the company's cost burden through alliance agreements, joint research and joint development with companies and academia, and public subsidies and grants have been set out as measures to stabilise management.